Dr. Reddys Laboratories, Inc.107 College Road EastPrinceton, NJ 08540Tel: 866-733-3952www.drreddys.com

2015 Dr. Reddys Laboratories, Inc. All rights reserved. RDY-1214-092 December 2014

Dr. R

edd

ys Laboratories, Inc. B

rand-to-G

eneric-to-Brand

Conversion G

uide

2015 E

dition

Compliments of

891

SECTION 1 Introduction .................................................................................. 2 7

SECTION 2 Dr. Reddys 2015 Product Portfolio .............................................8 - 12

SECTION 3 Generic Names to Brand Names .............................................. 13 - 60

SECTION 4 Brand Names to Generic Names .............................................61 - 108

SECTION 5 Clinical Resources ................................................................... 109 - 137

Available at Dr. Reddys3

Dear Healthcare Professional,

Good health is always the goal. At Dr. Reddys North American Generics, we realize this and we continue to take steps going forward to make affordable healthcare a reality. With renewed focus and investment, were committed to accelerating access to innovative, cost-effective medicines and providing you with the best products at the best value every day.

The easy-to-use 2015 Brand-to-Generic-to-Brand Conversion Guide is another way we deliver value to customers. The complimentary pocket guide is yours to keep, featuring more than 1,000 drugs and useful clinical resources to assist you with conversions, calculations, assessments and more. It includes:

Generic-to-Brand Conversion Guide An alphabetical listing of generic products, cross-referenced to the corresponding brand names

Brand-to-Generic Conversion Guide An alphabetical listing of brand products, cross-referenced to the corresponding generic names

Clinical Resource Section Resources such as charts on liver function assessment, equi-analgesic doses, and high-alert drugs

Product Portfolio The complete Dr. Reddys product portfolio is presented in section 2 of the guide. Throughout the guide, Dr. Reddys products are printed in color.

As the 2015 Brand-to-Generic-to-Brand Conversion Guide earns its place as a valuable tool in your clinical setting, know that all of us at Dr. Reddys take great pride in, and are committed to, providing you with important resources for the care of your patients.

Sincerely,

Dr. Reddys Laboratories, Inc.

The strategic benefits of vertical integration help ensure that Dr. Reddys products are delivered on time. Dr. Reddys manufacturing facilities, with a proven record of regulatory compliance, follow cGMP guidelines in the production of finished dosage forms. Four finished dosage facilities are already in place in North American Generics along with 9 API facilities. The investments that the company is making today, in its infrastructure, technology and operations, will help to ensure sustained growth by delivering value to its customers while striving to ensure that critical drugs reach those individuals who require them.

With a deep understanding of patient needs and our determination to meet those needs by resolving the challenges that only a few can, were pushing ourselves to reach higher levels of excellence. Together, we can make the world a healthier place.

Compliments of Dr. Reddys Laboratories, Inc.

4

Good Health Matters

At Dr. Reddys North American Generics, we are in the business of good health striving every day to do what matters most to patients:

Bringing expensive medicines within their reach by helping reduce the cost of therapy

Offering products that provide convenience, safety, and efficacy

Provide education and support to help manage disease better

Ensuring that products are always on the shelf by partnering with our customers

Working with our partners to help them meet patient needs

We dont see medicines as just molecules, but as tools that will help people get back to health and promote wellness among them. It is part of an exciting, yet complex journey that began three decades ago and continues to fuel our growth today.

Dr. Reddys is now ranked 8th* among the leading generic companies in the United States, with a growing portfolio and pipeline of products across major therapeutic categories including gastrointestinal, cardiovascular, pain management, oncology, anti-infectives, pediatrics, and dermatology. More than 60 prescription products are already marketed under the Dr. Reddys label in over 280 dosing presentations and theres more on the way, thanks to an aggressive product pipeline with 72 ANDAs pending approval, of which 45 are Para IV certifications and 11 have First To File status.

The company is also uniquely positioned to support Rx-to-OTC switches through its Private Label OTC Group which markets 9 products more than 150 store-brand packaging presentations.

54

*Based on September 2014 IMS Sales. Source: IMS Health, National Prescription Audit, September 2014.

Dr. Reddys Laboratories, Inc. does not assume and hereby expressly disclaims any liability whatsoever for any errors or omissions in such information or for any of the products listed.

All brand names listed in the BRAND columns are trademarks and are the property of their respective owners. To request additional copies, please contact:

2015 by Dr. Reddys Laboratories, Inc.

Customer Service Telephone 866-733-3952

Customer Service Fax 866-733-3939

Medical Information Questions related to: Medical Inquiries Product Complaints Adverse Events Toll Free (9:00AM-7:00PM ET): 1-888-375-3784 Email: medinfo@drreddys.com

Important Notice

The 2015 Brand-to-Generic-to-Brand Conversion Guide has been produced to provide an easy-to-use reference source of generic names, brand names, and other selected drug information. While the 2015 Brand-to-Generic-to-Brand Conversion Guide is an extensive list, it is not a complete list of all the generic and brand-name drugs currently available.

The 2015 Brand-to-Generic-to-Brand Conversion Guide should not be relied upon in making generic substitution determinations. It is the healthcare professionals responsibility to consult and follow all applicable federal and state laws and regulations when prescribing or dispensing pharmaceuticals and, as always, the full prescribing information should be consulted. In reaching a professional judgment, healthcare professionals should thoroughly understand the options available for any clinical application, the potential effectiveness of each product, the associated risks and side effects, and possible interactions. This knowledge should be considered in light of the special circumstances of the patient, for each patient is unique.

76

n Available as a Dr. Reddys product. 9

DR. REDDYS PRODUCT BRAND

BRAND GENERIC

AMLODIPINE BESYLATE + ATORVASTATIN CALCIUM TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . .CADUET

AMLODIPINE BESYLATE+ BENAZEPRIL HCl CAPSULES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .LOTREL

AMOXICILLIN CAPSULES AND TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . AMOXIL

AMOXICILLIN+CLAVULANATE POTASSIUM ER TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . AUGMENTIN XR

AMOXICILLIN+CLAVULANATE POTASSIUM ES SUSPENSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .AUGMENTIN

AMOXICILLIN+CLAVULANATE POTASSIUM SUSPENSION AND TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .AUGMENTIN

AMOXICILLIN POWDER FOR OS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . AMOXIL

ATORVASTATIN CALCIUM TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LIPITOR

AZACITIDINE FOR INJECTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . VIDAZA

CIPROFLOXACIN TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .CIPRO

CLOCORTOLONE PIVALATE CREAM, 0 .1% . . . . . . . . . . . .CLODERM CREAM, 0.1%

CLOPIDOGREL BISULFATE TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .PLAVIX

DECITABINE FOR INJECTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .DACOGEN

DESLORATADINE ORALLY DISINTEGRATING TABLETS . . . . . . . . . . . . . . . . . . . . . . . . .CLARINEX REDITABS

n Available as a Dr. Reddys product. 11

DR. REDDYS PRODUCT BRAND

BRAND GENERIC

10

DR. REDDYS PRODUCT BRAND

n Available as a Dr. Reddys product.

LEVALBUTEROL INHALATION SOLUTION . . . . . . . . . . . . . . . . . . . . . . XOPENEX

LEVOFLOXACIN TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . LEVAQUIN

MEPROBAMATE TABLETS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .MILTOWN

METOPROLOL SUCCINATE ER TABLETS . . . . . . . . . . . . . . . . . . . . . . . . TOPROL-XL

MI